Compare DTSS & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTSS | NCNA |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.8M |
| IPO Year | 2015 | 2017 |
| Metric | DTSS | NCNA |
|---|---|---|
| Price | $0.92 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.7K | 31.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $71,616,820.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 198.70 | N/A |
| 52 Week Low | $0.64 | $0.03 |
| 52 Week High | $2.70 | $10.00 |
| Indicator | DTSS | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 36.23 |
| Support Level | $0.81 | $2.07 |
| Resistance Level | $0.98 | $2.27 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 45.72 | 51.85 |
Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.